Generating and validating renewable affimer protein binding reagents targeting SH2 domains
Scientific Reports · 2024
DOI: 10.1038/s41598-024-79357-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Sophie J Heseltine und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular and Cellular Biology, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: src Homology Domains, GRB2 Adaptor Protein, Protein Binding. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Medical Research Council.
Abstract (Originalsprache)
Despite SH2 domains, being pivotal in protein interactions linked to various diseases like cancer, we lack specific research tools for intracellular assays. Understanding SH2-mediated interactions and creating effective inhibitors requires tools which target individual protein domains. Affimer reagents exhibit promise, yet their potential against the extensive SH2 domain family remains largely unexplored. Our study aimed to bridge this gap by identifying Affimer reagents that selectively bind to 22 out of 41 SH2 domains. These reagents enabled a medium-throughput screening approach resembling siRNA studies, shedding light on their functionality. Notably, select Affimers demonstrated the ability to curtail the nuclear translocation of pERK, with Grb2 being a prominent target. Further analyses revealed that these Grb2-specific Affimer reagents displayed competitive inhibition with impressive metrics: IC50s ranging from 270.9 nM to 1.22 µM, together with low nanomolar binding affinities. Moreover, they exhibited the ability to pull down endogenous Grb2 from cell lysates, illustrating their efficacy in binding the Grb2 SH2 domain. This comprehensive assessment underscores the potential of Affimer reagents as domain-specific inhibitors. Their viability for medium/high-throughput phenotypic screening presents a promising avenue via which to identify and characterize potential drug targets within the SH2 domain family.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.
- Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK.
- Avacta Life Sciences, Wetherby, UK.
- School of Chemistry, University of Leeds, Leeds, UK.
- School of Molecular and Cellular Biology, University of Leeds, Leeds, UK. d.c.tomlinson@leeds.ac.uk.
- Astbury Centre for Structural and Molecular Biology, University of Leeds, Leeds, UK. d.c.tomlinson@leeds.ac.uk.
Förderung
- Biotechnology and Biological Sciences Research Council
- Medical Research Council
Zitieren
APA
Heseltine, S. J., Billenness, G. J., Martin, H. L., Tiede, C., Tang, A. A. S., Foy, E., Reddy, G., Gibson, N., Johnson, M., Webb, M. E., McPherson, M. J., & Tomlinson, D. C. (2024). Generating and validating renewable affimer protein binding reagents targeting SH2 domains. Scientific Reports. https://doi.org/10.1038/s41598-024-79357-4
Vancouver
Heseltine SJ, Billenness GJ, Martin HL, Tiede C, Tang AAS, Foy E, et al. Generating and validating renewable affimer protein binding reagents targeting SH2 domains. Scientific Reports. 2024. doi:10.1038/s41598-024-79357-4
BibTeX
@article{Heseltine2024,
author = {Heseltine, Sophie J and Billenness, Gregory J and Martin, Heather L and Tiede, Christian and Tang, Anna A S and Foy, Eleanor and Reddy, Grace and Gibson, Naomi and Johnson, Matt and Webb, Michael E and McPherson, Michael J and Tomlinson, Darren C},
title = {Generating and validating renewable affimer protein binding reagents targeting SH2 domains},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-79357-4}
}
EUVIMED